Bioavailability of a New Generic Formulation of Mycophenolate Mofetil MMF 500 Versus CellCept in Healthy Adult Volunteers

Transplantation Proceedings

Volumn 39, Issue 4, 2007, Pages 1233-1236

  Masri, M A ^a   Rizk, S ^a   Attia, M L E ^b   Barbouch, H ^b   Rost, M ^c  

^a TransMedical Drug Evaluation Center   (Lebanon)

^b Laboratories Medis Tunis   (Czech Republic)

^c UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; HEPARIN; LIVER ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CHEMISTRY; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUID INTAKE; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; URINALYSIS;

ADULT; BIOLOGICAL AVAILABILITY; DRUGS, GENERIC; FEMALE; HUMANS; MALE; MYCOPHENOLIC ACID; REFERENCE VALUES; TABLETS;

EID: 34249038135     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.03.055     Document Type: Article

References (23)

1. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for the prevention of acute rejection. Lancet 345 (1998) 1321
2. The International Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61 (1996) 1029
3. The Mycophenolate Mofetil Renal Refrectory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 61 (1996) 722
4. Halloran P., Mathew T., Tomlanovich S., et al. Mycophenolate mofetil in renal allograft receipents. A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplnatation 63 (1993) 39
5. Grinyo J.M., Gil-Vernet S., Seron D., et al. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplanation 63 (1997) 168
6. Stephan A., Barbari A., Kamel G., et al. A one-center experience with a shortcourse of mycophenolic acid. Transplant Proc 31 (1999) 3289
7. Committee for Proprietary Medicinal Products (CPMP). Notes for guidance on the investigation of bioavailability and bioequivalence (2001). http://www.emea Available: http://www.emea. Accessed October 22, 2003
8. Food and Drug Administration Center for Drug Evaluation and Research: Approved drug products with therapeutic equivalence evaluations prescribing information. Available: http://www.fda.gov. Accessed October 22, 2003
9. Food and Drug Administration (FDA). Bioavailability and bioequivalence requirements. Fed Regist 57 (1992) 17997
10. Masri M.A., Andrysek T., Rizk S., et al. The role of generics in transplantation. TM-MMF vs Cellcept in healthy volunteers. Transplant Proc 36 (2004) 84
11. Masri M.A., Stephan A., Barbari A., et al. Cyclosporine formulations: is there really a difference?. Transplant Proc 32 (2000) 1468
12. Masri M.A., Barbari A., Stephan A., et al. Safe and cost effective conversion from Neoral to Consupren soft gelatin capsules in stable renal transplant patients: a 1-year study. Transplant Proc 31 (1999) 3302
13. Stephan A., Masri M.A., Barbari A., et al. A one-year comparative study of Neoral vs Consupren in de novo renal transplant patients. Transplant Proc 30 (1998) 3533
14. Barbari A., Stephan A., Kamel G., et al. Experience with new cyclosporine formulations: Consupren and Neoral in renal transplant patients. Transplant Proc 29 (1997) 2941
15. Stephan A., Barbari A., Masri M.A., et al. Evaluation of the new cyclosporine formulation, Consupren, in renal transplant patients. Transplant Proc 28 (1996) 1348
16. Masri M.A., Barbari A., Stephan A., et al. Cyclosporine pharmacokinetics in stable renal transplant patients: effect of formulation Sandimmun versus Consupren versus Neoral. Transplant Proc 28 (1996) 1318
17. Koehler J., Kuehnel T., Kees F., et al. Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine A in rats. Drug Metab Dispos 30 (2002) 658
18. Alloway R.R. Generic immunosuppressant use in solid organ transplantation. Transplant Proc 31 (1999) 2S
19. First M.R., Alloway R., and Schroder T.J. Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral. Clin Transplant 12 (1998) 318
20. Roza A., Tomlanovich S., Merion R., et al. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation 74 (2000) 1013
21. Qazi Y.A., Forrest A., Tornatore K., et al. The clinical and economic impact of 1:1 conversion from Neoral to Gengraf (2002) (abstract). ASN SA-P0505
22. Pollard S., Nashan B., Johnston A., et al. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Clin Ther 25 (2003) 1654
23. Masri M.A. The generics in transplantation and the rules on their use. Exp Clin Transplant 1 (2003) 65